Andere talen Shionogi & Co., Ltd.

Aandelen

4507

JP3347200002

Vertraagde tijd Japan Exchange Andere beurzen 08:00:00 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
7.343 ^JPY	0,00%		+3,42%	+8,02%

18/04	Shionogi & Co., Ltd. kondigt nieuwe gegevens aan van de Europese studie naar echt bewijs (PERSEUS) van Fetroja®/F etcroja® (cefiderocol)	CI
29/03	Shionogi rondt inkoop van maximaal 75 miljard yen aandelen af	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Shionogi & Co., Ltd. - Notice regarding introduction of a Restricted Stock Compensation Plan for Vice Presidents	23/04
Shionogi & Co., Ltd. - Notice Regarding Completion of Cancellation of Treasury Shares	19/04
ESCMID Global 2024, Shionogi presents real-world data demonstrating efficacy of Fetcroja, Fetroja in critically ill patients with certain difficult-to-treat bacterial infections	19/04
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares	19/04
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol)	18/04
Shionogi - The European Commission Grants Orphan Medicinal Product Designation for Zatolmilast, a Potential First-In-Class Treatment Being Investigated for Fragile X Syndrome	12/04
Shionogi Completes Up to 75 Billion Yen Share Buyback	29/03
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023.	28/03
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million.	22/03
FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd.	21/03
Shionogi & Co., Ltd. - Recognized as One of the Highest-Ranking Companies on the Supplier Engagement Rating by CDP for the Fourth Consecutive Year	08/03
GSK Unit ViiV Healthcare's Injectable HIV Treatment Shows 'Superior Efficacy' in Late-stage Trial	07/03
Shionogi & Co., Ltd. - Notice Regarding the Status of Acquisition of Own Shares	06/03
Shionogi Announces Xocova Obtained Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	06/03
Shionogi Buys Back Shares Worth Nearly 12 Billion Yen	06/03
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses \| GSK	05/03
GSK says ViiV's cabotegravir study supports longer HIV dose interval	05/03
GSK's ViiV Healthcare Says Four-month Interval Between Doses Possible for HIV Treatment Cabotegravir	05/03
Shionogi & Co., Ltd. Announces Xocova Obtains Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	05/03
US urges court to preserve Obamacare mandate to cover cancer screenings, HIV drugs	04/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Shionogi & Co., Ltd.

Aandelen

4507

JP3347200002

Andere talen

Filters